As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.
8 Analysts have issued a Lexaria Bioscience Corp forecast:
8 Analysts have issued a Lexaria Bioscience Corp forecast:
May '25 |
+/-
%
|
||
Revenue | 0.62 0.62 |
63%
63%
|
|
Gross Profit | 0.61 0.61 |
61%
61%
|
|
EBITDA | -11 -11 |
143%
143%
|
EBIT (Operating Income) EBIT | -11 -11 |
137%
137%
|
Net Profit | -11 -11 |
135%
135%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lexaria Bioscience Corp. is a proprietary drug delivery technology company. Its technology DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption, reduces time of onset, and masks unwanted tastes for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a tobacco producer for the development of smokeless, oral-based nicotine products. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.
Head office | United States |
CEO | Mr. Christopher |
Employees | 7 |
Founded | 2004 |
Website | www.lexariabioscience.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.